Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JR...IMO, Brave will show that Vascepa can slow the onset of Alzheimers and/or slow its progression, but not cure it once it is established, since Alzheimers is a chronic disease.
Its analogous to Vascepa's effect on atherosclerosis, in which Vascepa can slow the progression of atherosclerosis and the ills brought on by it...but not completely stop it or CVD....It is also similar to the aging process...in which Vascepa has anti-inflammatory effects on many conditions, which have to do with aging...but not to cure them...and in the end, we all have to die.
Unfortunately , the picture is not as clear to patients using Vascepa, as when penicillin is used by them to end their infections.
Tal....Lequembi has many problems including as severe side effects...such as intracranial bleeding, large expense, unimpressive results... and the need to be given IV by a Doc or a nurse.
The Brave study uses Vascepa as an oral, inexpensive safe alternative treatment for Alzheimers ...The study starting on June 2017, and utilizing serial spinal taps... is due to be completed by the University of Wisconsin by the end of next month....Vascepa could be outstanding competition for Lequembi in the slowing of the progression of Alzheimers.
Even if there are only moderately good results from the Brave study, the FDA would seem likely to look favorably on Vascepa as a treatment for this terrible debilitating disease.
Diabetes was one of the risk factors that the FDA identified in their Adcom in their unanimous approval of Vascepa for the treatment of CVD.
Pdude...KM hired his friends at Biologics, a company which turned out to be missing in action...then he wasted Amarin millions of dollars by hiring a large number of salesmen prematurely, all the while, failing to recognize Germany's well known history of not providing adequate reimbursement for drugs for their patients....Then PWO, following his own interests, failed to grant standing to Marjac's appeal to SCOTUS even when was working gratis...on on a very convincing over 200 page brief, pointing out the fraud perpetrated by Hickma on Amarin in the ninth circuit case...
KM and PWO constantly were putting their own interests ahead of Amarin's...Sure his goal has been to profit from his investment in Amarin... but I have confidence that we retail investors will also participate in those profits.
Unlikely that Holt traded today since he had information, not yet known publicly.
ILT was making antisemitic remarks and I was directing my post to him.
YOU ARE FULL OF CRAP!!! NUF SAID
ILT "If I were Denner, I would go after the fraud with standing. We didn't have it the first time, cough cough, but Denner does"
I Agree...Marjac(i. e. attorney Michael Kasonoff of New Jersey) wrote an excellent legal brief of about 260 pages for the consideration of SCOTUS, which rejected it due to lack of standing...There is no time limit for fraud on the court... and justice for the fraud is still waiting.
CBB..I believe it was an unfortunate confluence of Judge Du's inexperience, along the poor performance of Amarin's lawyers...that allowed Hikma to defraud the court and that lead to the tragic error, which has resulted in the occurence of so many CVD's, which could have been prevented.
One..."As part of the agreement, Amarin will receive an upfront payment as well as pricing and reimbursement and sales milestone payments based on net sales of the product.
-what is the upfront payment?
-What is total amount of the milestone payments?
-What is the status of approvals in these counties?
-Its probably too soon to ask about reimbursements.
KIWI...Increased volume feeds on itself...i.e by word of mouth.
1000 sales at $10 profit/sale is preferable to 100 sales at $20profit/sale
So..even with decreased prices, profits can grow....
As the old saying goes...You can lose a little bit on every sale, but you can make it up on the volume.
KIWI...Tony(JL) was fortunate enough to have a lawyer daughter, who explained to him that Hikma's real goal was not to just break Amarin's high trig patent for its measly rewards, but to infringe on Amarin's CVD patent with its handsome rewards...
We now know that Hikma was able to fraudulently manipulate the court through an inexperienced judge and achieve their goal of cashing in by a 'skinny label' infringement of Amarin's CVD patent...The result has been to cripple Vascepa and Amarin, thereby, diminishing their assets, and, with it, diminishing Amarin's ability to tell patients about Vascepa and save the lives of many patients, who might have been able to survive a CVD had they been able to know about the drug...and prevented Amarin from further developing Vascepa by a FDC.
Canam...I disagree...
Denner is a relatively young man with many more battles to fight...He has his reputation on the line...as well as his cash.
"$1.15 to $2.50 is a significant move to anyone not 'hollering' about Amarin being $20+ once"...
I don't 'holler" as sometimes tornado do...I speak with quiet calm and confidence in the future of Vascepa and Amarin.
"Denner would NEVER engineer a way to take control for pennies on the dollar, it's not his MO"
I do agree with you there...even though I understand you were only being your old 'tornado' self.
Your advise was appropriate for the time when Amarin's price was over $20/sh, but not at this time...When the price rises significantly, I will reconsider it.
Tats...When I took the name Ziploc, it was because I thought a bright future for Vascepa and for Amarin was "in the bag"..I still do.
Tatsumaki...I looked up, on Google, the meaning of your IHUB moniker...It is "tornado of terror"...
IMO you are certainly living up to that name....You are obviously intelligent but I believe you are playing this board... We shareholders are serious investors with serious money at stake...Please keep your comments equally serious and equally rational....Dr Denner is NOT invested in Amarin to make some interest on a loan...nor is he interested in taking over the company himself and then selling it for pennies...It is not his style, nor his reputation.
JR...You may be correct...and, if so, A BP, which owns Amarin, can better afford the wait than Amarin can.
JR...In the short term, I expect Amarin to get approval for Vascepa in China along with a decision on remunerations for Vascepa in China at low prices...i.e. through Amazon's partner. Eddingpharm...This may lead Amarin to issue an AG in the U.S....Amarin,with the added income from sales in China and from the U.S. AG, will be able to have the assets to market Vascepa globally at low prices and high volumes...I have long thought that this is the future path for Vascepa.
CBD...I agree your thinking about the benefits of Amarin's partnering with a large generic company for an AG of Vascepa in the US...
A generic company, which partners with Amarin on an AG of Vascepa in the US, could compete well on pricing to patients with the pricing to patients from other competing generic companies...which are also marketing a gV in the US at the same time ...and Amarin and Amarin's generic partner could benefit from the advantage of having greater purchasing power for their EPA from their manufacturers...due to the larger volumes of EPA, used to supply markets in Europe as well as in the US...This would lead to lead to lower prices for the supplies of EPA for Amarin and for its generic company partner...than the prices for the supplies of EPA for competing generic companies, which also need to also buy EPA from the same manufacturers.
At the same time, Amarin could continue with its sales of branded Vascepa in Europe...and Amarin could continue to benefit from lower prices for its EPA due to their higher volume purchases of EPA for the AG IN THE US and for their branded Vascepa IN EUROPE.
A BP, with many drugs on the market, has an advantage over a small company with one drug...when it comes to negotiating with governments....A BP, with bountiful assets, can accept lower prices for a certain drug and higher prices for another of their drugs...as benefits the interests of both parties in the areas of supply and pricing.
In the case of Amarin, they have too much supply, but they can't lower their prices for Vascepa, in return for increased volume...because they can't sustain a temporary loss of income from Vascepa...A BP would be better able to deal with problems of this nature.
What Vascepa needs now is credibility, especially after the fiasco with German refusal to pay a reasonable price for the drug...Each approval in Europe and assignment of a reasonable price contributes to that credibility...Eventually this process will pay off for Vascepa and for Amarin.
I do believe that a BP could speed up this process
Denisk... "Mitigate was never intended as a clinical trial to reveal additional positive medical results for using Vascepa/ Vazkepa was only done to promote the distribution and sale of Vascepa to KP customers and patients.Total waste of time to talk about it." ...WRONG!!
IMO KP cares little to nothing about the distribution and sales of Vascepa to their customers...except as this might relate to KP's saving money by preserving the health of their customers.
Amarin, which provided the Vascepa to KP for for the study, as well as we investors, deserve to know the reason for it being stopped...and I am confident that the results will become known soon.
I wonder whether Hikma filed its false Sherman antitrust complaint against Amarin in the expectation that the filing might then induce Amarin to compromise and agree to withdraw its substantive CVD infringement complaint against Hikma.
Amarin's destiny changed after the judge Du debacle...Prior to Judge Du, JT planned to capitalize on Vascepa's future earnings and make Amarin into a BP... and GIA had made sense until then...But after the invalidation of Amarin's high trig patent, JT failed to understand that GIA was no longer practical...and therefore Amarin's best future prospects lay with a BP..rather than a GIA policy....I believe Denner understands this well...as does his BOD.
KIWI...QUOTE..."They can afford to run their generic V as a loss leader ...until AMRN drops out of the US market ."
Generic companies are not doing so well lately. Therefore...
-Generic companies will be hesitant to sell large volumes of gV at a loss to them.
-Vascepa will not drop out of the US market...It will, in any event, be taken over by a BP, which will continue it on a global scale...with new EPA configurations and new EPA products, as previously discussed.
Vascepa is not going away..although Amarin will eventuall be bot by a BP
Amarin currently has no debt and $300M in cash...Why would Denner and the board want to take on debt now?
Capt....Thanks for the data...IMO, lower prices... and higher volumes seem to be the path forward in Amarin's future.
Approval in mainland China and successful marketing by Eddingpharm will be important next steps for these trends...Amarin will, at that time, receive lower prices for their EPA from manufacturers, due to Amarin's high volume purchases globally....An AG for the US, in support of these trends, may also be up for consideration soon.
Amarin will, at that juncture, have sufficient assets to pursue other indications for EPA and other configurations of EPA drugs
I found this an interesting article on how Alzheimers researches are probably wrong in emphasizing Amyloid as a cause of the disease rather than inflammation.
Recent good news from the Hong Kong exchange...
"Edding Group Company Limited
07/07/2023OC Announcement - APPOINTMENT
23/06/2023Application Proof (1st submission)"
Apparently Edding is seriously pursuing an IPO, which would financially enable them to promote Vaskepa in China, where Amarin has already received approval.
Accessing the China market could pave the way for higher volumes at lower prices in China, the US(where Amarin could immediately do an AG) and ROW and make Vaskepa a truly global drug....and open the door for FDC drugs.
The future for Amarin is clear...Vascepa needs to be sold at lower prices and higher volumes...Amarin is now, more than ever, ready to enact this policy...especially when the Chinese market for this wonder drug starts soon...As JL predicted long ago, this strategy is destined to usher in Vascepa's long term destiny...Judge Du's incompetence simply hastened the process for this to occur.
Has Amarin ever applied for a patent for Vascepa for the slowing of the progression of Alzheimers disease...on the basis of Vascepa's anti-inflammatory effect?...If not, why not?
Apparently the medical researchers at the University of Wisconsin(in collaboration with the Veterans administration), thought that Vascepa treatment had enough of a chance to positively delay Alzheimers...to warrant an invasive study to examine this subject...The results of this study(the Brave study) should be available this summer.
A safe, conveniently administered and inexpensive drug, as an alternative to the present unsafe, expensive and mediocre drugs , which have recently won FDA approval, is much needed ASAP.
Thanks Capt...I find it interesting that licensing and royalty revenues increased by 60% in Q3,2023 over Q2, 2023...When China agrees to approve payments to Amarin for Vascepa, this category could be substantial...even with low margins of profit for Amarin.
A positive cash flow or earnings in the Q3 would auger well.
Duke...It seems that this patent specifically interdicts a formulation of a fish oil product from combining with a statin and being marketed as a combo drug.
IMO a statin combined with Vascepa or an some other analogue of EPA will eventually be the way EPA is consumed for a myriad of conditions.
The FDA required the R-IT study, before affirming Vascepa for the CVD indication because 10 out of the 12 expert cardiologists on their 2013 Advisory committee did not agree that Vascepa "obviously" reduced CVD...and the FDA, at that time, demanded that Amarin provide further evidence from a five year study on 8000 patients...before they could conclude in 2019 that Vascepa, did succeed in reducing CVD events.
If generics can break the R-IT patent, they can break any patent.
Vascepa's largest competitor is not gV and not Lovaza...It is fish oil...which has far more sales than Vascepa, being sold in volume in every supermarket...and fish oil has been proven to be NOT helpful in reducing CVD events, plus it does not have Vascepa's many other beneficial effects...Amarin, somehow has to get the word out that Vascepa has been proven to provide many real health benefits that fish oil can not.
I view Vascepa as an anti-inflammatory drug...With that in mind, I wonder if there is any data on how it might be helpful to patients with serious allergies...including asthma.
JR...You are correct...The Marine patent(AMR101) for high trigs was approved by the FDA in 2012...The Anchor hearing was in 2014, in which the FDA Adcom refused to allow Amarin to have the CVD patent until completion of their R-IT study, which I believe was in 2019....Amarin had to borrow cash just in order to complete their study and and was required to use its patents as collateral for the loan...Hikma's investment was just in its legal fees with no Marine study or CVD study.
And now, gV is mainly being prescribed for the CVD indication.